Ligand Pharmaceuticals LGND Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's stock-based comp?
- Ligand Pharmaceuticals (LGND) reported stock-based comp of $10.6M in Q1 2026.
- How has Ligand Pharmaceuticals's stock-based comp changed year-over-year?
- Ligand Pharmaceuticals's stock-based comp increased by 35.2% year-over-year, from $7.84M to $10.6M.
- What is the long-term trend for Ligand Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's stock-based comp has grown at a 4.8% compound annual growth rate (CAGR), from $38.78M to $46.85M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.